Eledon Pharmaceuticals, Inc.

In honor of #DiabetesAwarenessMonth, this article from T1D Strong provides an overview of results from the UChicago Medicine study assessing an #immunosuppression regimen including our investigational therapy, tegoprubart, for the prevention of islet #transplant rejection in subjects with type 1 #diabetes: https://lnkd.in/gDj54yKx

During National #FamilyCaregiversMonth, we are showing our appreciation for caregivers throughout the #transplant community who continue to make a positive difference for their families through their selflessness and compassion. Check out the graphic below for insights from caregivers shared by American Kidney Fund!

During National #FamilyCaregiversMonth, we are showing our appreciation for caregivers throughout the #transplant community who continue to make a positive difference for their families through their selflessness and compassion. Check out the graphic below for insights from caregivers shared by American Kidney Fund!

Guided by our mission to achieve #OneTransplantForLife, our Phase 2 BESTOW clinical trial is focused on advancing research in #immunosuppression to support the prevention of rejection in #KidneyTransplantation. Learn more about the ongoing study here: https://bestowstudy.com/

David-Alexandre "DA" Gros, M.D., our CEO and proud alum of the The Johns Hopkins University School of Medicine, recently sat down for an interview with the The Johns Hopkins News-Letter to discuss the history of Eledon and the important progress we have made in advancing #immunosuppression research in several key areas including kidney allotransplantation, islet #transplantation, and heart and kidney xenotransplantation. Read more: https://lnkd.in/epz6ju8s

Check out this segment from Fox 32 Chicago highlighting the story of Marlaina and her experience as a participant in a clinical study at UChicago Medicine evaluating an #immunosuppression regimen including our investigational therapy, tegoprubart, for the prevention of islet #transplant rejection in subjects with type 1 #diabetes: https://lnkd.in/ez25JYE3

Check out the latest episode of The BioHub Podcast featuring an interview with our CEO David-Alexandre "DA" Gros, M.D., highlighting expert perspectives on entrepreneurship in #LifeSciences as well our progress in advancing #immunosuppression research to protect transplanted organs. Thank you Tom Weir for the great discussion!?https://lnkd.in/eBnNF9ta?Avetix Group

In November, the #NationalDonorSabbath is observed as a three-day interfaith celebration that unites communities to build awareness of the critical organ shortage crisis and honor the lifesaving generosity of organ donors. We are proud to recognize this special initiative as we continue our work to help increase the availability of donor organs by advancing #immunosuppression solutions that may increase #transplant function and longevity. Donate Life America

We are pleased to share that topline results from the Phase 2a clinical trial evaluating our investigational therapy, tegoprubart, in patients with amyotrophic lateral sclerosis (#ALS) have been published in PLOS Medicine. Read more: https://lnkd.in/eqt2yhj3 Thank you to the members of the ALS community, investigators, and clinical trial site staff whose valued contributions supported the advancement of this research.

This #NationalNursePractitionerWeek, we are pleased to join the American Association of Nurse Practitioners in honoring NPs for their expertise and leadership. In our work to advance innovative #immunosuppression research to support the prevention of transplant rejection, we recognize the essential role NPs play in delivering quality care to #transplant recipients. Learn more about #NPWeek here: https://npweek.aanp.org/